Hargreaves Lansdown

Abingdon Health reaches £6.3m settlement with DHSC

Tue 28 June 2022 11:19 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Rapid testing kits manufacturer Abingdon Health has reached a settlement agreement with the Department for Health and Social Care on outstanding invoices payable to the group for lateral flow tests and component stock.

Abingdon Health said on Tuesday that it will receive a contractually required cash payment of £6.3m from DHSC on or before 22 July, with £1.5m of the cash payment to be held under charge until the outcome of an ongoing judicial review.

The AIM-listed group also stated ownership of all outstanding component stock procured on behalf of DHSC in 2020 and 2021 will be transferred to the company, while it will also receive joint ownership of the intellectual property of its AbC-19 Covid-19 antibody test, and make lower royalty payments to DHSC on sales of said test.

Abingdon also highlighted that the cash received from DHSC will provide it with additional working capital to be deployed in order to help fund various growth initiatives currently underway.

As of 1210 BST, Abingdon shares had surged 52.35% to 14.47p.

Reporting by Iain Gilbert at Sharecast.com

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More AIM news from ShareCast

    No results were found